paper
summar
result
obtain
multiplex
pcr
screen
human
clinic
sampl
respiratori
virus
correspond
data
obtain
passag
virusposit
sampl
mdck
cell
use
resplexii
qiagen
multiplex
pcr
posit
result
obtain
clinic
sampl
collect
influenza
season
germani
overal
distribut
posit
result
influenza
influenza
b
adenoviru
bocaviru
coronaviru
enteroviru
metapneumoviru
parainfluenza
viru
rhinoviru
respiratori
syncyti
viru
rsv
doubl
infect
influenza
viru
togeth
anoth
viru
found
adenoviru
b
e
bocaviru
coronaviru
enteroviru
rhinoviru
virus
rapidli
lost
upon
passag
mdck
cell
condit
appli
influenza
viru
passag
clinic
sampl
influenza
viru
virus
found
also
subject
passag
mdck
cell
use
lower
inoculum
dilut
normal
appli
prepar
contain
influenza
viru
total
dilut
origin
sampl
posit
result
differ
virus
turn
neg
alreadi
passag
mdck
cell
result
demonstr
practic
condit
appli
grow
influenza
virus
contamin
virus
effect
remov
passag
mdck
cell
combin
superior
isol
effici
mdck
cell
appear
highli
suitabl
use
altern
embryon
egg
isol
propag
influenza
vaccin
candid
virus
influenza
viru
isol
monitor
epidem
influenza
activ
select
candid
vaccin
strain
tradit
conduct
cultiv
embryon
hen
egg
due
receptor
limit
egg
passag
caus
adapt
mutat
haemagglutinin
eggadapt
mutat
revert
subsequ
passag
mammalian
cell
may
alter
antigen
properti
receptor
bind
site
also
critic
bind
site
viru
inhibit
protect
antibodi
contrast
eggpassag
viru
mammalian
cellgrown
influenza
viru
preserv
sequenc
origin
human
clinic
sampl
last
decad
worldwid
nation
influenza
centr
almost
complet
chang
influenza
viru
isol
egg
cultur
cell
cultur
mainli
use
mdck
cell
chang
cell
cultur
stimul
rel
eas
conduct
multipl
isol
cell
cultur
also
better
antigen
match
mdckisol
virus
field
strain
increas
difficulti
recov
isol
embryon
egg
particularli
h
n
subtyp
also
contribut
chang
cell
cultur
sever
compani
current
develop
cell
culturebas
influenza
vaccin
first
vaccin
produc
mdck
vero
cell
licens
distribut
interpandem
trival
pandem
h
n
vaccin
use
convent
recommend
refer
virus
vaccin
still
origin
eggderiv
viru
isol
correspond
highgrowth
reassort
regulatori
concern
mainli
regard
introduct
adventiti
agent
rais
candid
vaccin
strain
deriv
directli
uncharacteris
uncontrol
cell
line
collabor
studi
initi
investig
growth
yield
influenza
virus
differ
cell
line
effici
fidel
influenza
viru
isol
suitabl
vaccin
manufactur
differ
cell
substrat
growth
studi
wide
rang
potenti
contamin
virus
conduct
risk
assess
made
compar
eggderiv
cellpassag
influenza
virus
regard
risk
carri
adventiti
virus
vaccin
manufactur
process
assess
indic
comparison
manufactur
embryon
egg
introduct
vero
cell
increas
risk
transmit
variou
virus
vaccin
process
wherea
use
mdck
cell
reduc
overal
risk
due
limit
permiss
viral
growth
mdck
cell
exert
filter
effect
human
adventiti
virus
embryon
egg
assess
presenc
coisol
virus
influenza
viru
isol
recov
mdck
cell
articl
provid
specif
data
kind
frequenc
coinfect
respiratori
virus
human
influenza
viruscontain
sampl
fate
coinfect
virus
passag
mdck
cell
nasal
pharyng
sampl
influenza
season
provid
clinic
diagnost
laboratori
locat
stuttgart
germani
sampl
patient
acut
respiratori
tract
infect
obtain
physician
mainli
southern
germani
sent
diagnost
laboratori
liquid
viru
transport
medium
aliquot
clinic
specimen
laboratori
number
anonym
identifi
sent
novarti
vaccin
marburg
germani
weekli
courier
servic
transport
sampl
store
c
directli
receipt
sampl
mdck
cell
inocul
detail
see
sampl
materi
cultur
harvest
day
incub
cellfre
supernat
aliquot
store
c
use
mdck
suspens
cell
novarti
work
cell
bank
cultiv
ml
dispos
spinner
flask
corn
cdm
medium
chemic
defin
growth
medium
use
cell
propag
mdck
cdm
lonza
passag
interv
day
cell
grew
initi
seed
densiti
cellsml
densiti
cellsml
infect
ml
cell
seed
ml
filter
tube
tpp
transadingen
switzerland
cell
densiti
cellsml
cell
cdm
medium
dilut
ratio
mdck
pfm
medium
proteinfre
medium
gibco
invitrogen
supplement
penicillinstreptomycin
solut
sigma
iuml
trypsin
obtain
total
cultur
volum
ml
ad
viral
inoculum
dilut
ml
infect
medium
predilut
sever
log
step
start
total
dilut
least
inocul
cultur
incub
c
day
co
atmospher
shaker
incub
kuhner
birsfelden
switzerland
viru
harvest
cell
separ
centrifug
g
min
supernat
recov
unless
use
freshli
eg
haemagglutin
test
subsequ
passag
aliquot
supernat
frozen
c
haemagglutin
ha
test
done
harvest
materi
defin
start
materi
next
passag
ha
test
perform
ubottom
microwel
plate
greiner
bioon
use
l
serial
log
dilut
pb
ph
test
sampl
l
chicken
guinea
pig
red
blood
cell
pb
ph
result
read
min
chicken
erythrocyt
min
guinea
pig
erythrocyt
incub
ambient
temperatur
within
temperatur
rang
c
two
differ
kind
red
blood
cell
use
sinc
actual
h
n
influenza
strain
react
chicken
red
blood
cell
materi
highest
log
inoculum
dilut
show
clearli
posit
ha
reaction
previou
passag
use
follow
passag
extract
viral
dna
rna
clinic
specimen
cultur
supernat
perform
nucleic
acid
isol
kit
magna
pure
compact
extract
system
roch
qiasymphoni
virusbacteria
midi
kit
qiagen
qiasymphoni
robot
system
resplex
ii
multiplex
pcr
panel
qiagen
use
accord
manufactur
instruct
test
appli
rtpcr
revers
transcript
pcr
reaction
onestep
rt
pcr
kit
qiagen
combin
two
pair
specif
primer
target
enzym
mix
contain
omniscript
tm
sensiscript
tm
revers
transcriptas
hotstartaq
tm
dna
polymeras
dntp
mix
contain
mm
dntp
primer
mix
consist
mixtur
individu
primer
viral
target
carri
tail
target
sequenc
superprim
forward
backward
superprim
result
multiplex
pcr
read
liquichip
detect
system
consist
microspher
coat
targetspecif
hybrid
molecul
steptavidinbiotin
base
fluoresc
detect
reaction
give
individu
fluoresc
color
pattern
viral
target
result
read
evalu
qiaplex
mddrvo
beta
softwar
accord
manufactur
instruct
signal
valu
posit
valu
neg
valu
consid
question
result
method
result
given
count
median
fluoresc
intens
mfi
method
intend
design
use
quantit
resplex
ii
method
design
detect
differ
viru
speci
viru
subgroup
simultan
pathogen
target
gene
use
summar
tabl
independ
convent
inhous
qrtpcr
commerci
avail
pcr
method
use
confirm
resplex
result
clinic
specimen
method
accord
refer
summar
tabl
tabl
particular
interest
specimen
doubl
infect
influenza
viru
togeth
virus
detect
sampl
posit
question
result
virus
found
associ
influenza
viru
associ
virus
list
along
extra
remark
sampl
gave
question
result
mfi
adenoviru
b
e
sampl
sampl
passag
five
time
mdck
pf
cell
describ
section
addit
sampl
compar
tabl
also
use
passag
question
posit
bocaviru
contain
influenza
b
one
sampl
sampl
posit
coronaviru
associ
influenza
viru
b
clinic
specimen
could
cultiv
suffici
materi
shown
tabl
viru
detect
passag
influenza
viru
contamin
virus
lost
passag
tabl
also
list
total
dilut
origin
sampl
passag
passag
one
sampl
see
sampl
tabl
viru
could
recov
passag
lower
dilut
order
detect
virus
list
tabl
reflect
count
found
resplex
method
coinfect
virus
lower
count
influenza
viru
sampl
highest
count
enteroviru
similar
count
rhinoviru
influenza
viru
sampl
higher
count
adenoviru
influenza
viru
howev
note
resplex
method
quantit
method
similar
way
sampl
posit
question
multiplex
pcr
result
virus
influenza
viru
also
cultiv
passag
mdck
cell
shown
tabl
two
passag
usual
suffici
elimin
viru
almost
sampl
test
neg
three
virus
detect
origin
sampl
still
gave
weak
resplex
signal
second
cell
cultur
passag
one
coronaviru
signal
question
level
enteroviru
one
rsv
question
level
consid
total
dilut
origin
sampl
second
passag
possibl
origin
sampl
contain
virus
remain
weakli
posit
passag
without
viru
growth
test
third
cultur
passag
repres
dilut
clinic
sampl
three
sampl
test
neg
resplex
ii
indic
viru
growth
weakli
posit
test
result
passag
obvious
due
residu
viru
origin
clinic
sampl
tabl
show
result
confirmatori
test
clinic
specimen
use
independ
convent
pcr
method
influenza
viru
refer
seed
produc
annual
basi
match
drift
influenza
strain
refer
virus
releas
vaccin
manufactur
recommend
publish
virus
subject
specif
test
adventiti
virus
correspond
vaccin
must
manufactur
test
distribut
within
month
order
meet
vaccin
schedul
short
timelin
convent
broad
spectrum
test
influenza
viru
seed
adventiti
agent
perform
time
particularli
one
consid
month
may
need
prepar
viru
independ
sourc
specif
antibodi
neutralis
influenza
viru
convent
eggderiv
viral
seed
commonli
assum
support
histor
safeti
record
mani
adventiti
virus
remov
egg
passag
cellderiv
influenza
viru
isol
consid
use
start
materi
vaccin
manufactur
inform
need
behaviour
adventiti
virus
cultiv
influenza
virus
suitabl
cell
substrat
studi
contribut
inform
cell
line
qualifi
influenza
vaccin
manufactur
result
present
seen
context
specif
design
growth
studi
wide
rang
potenti
contamin
virus
along
result
systemat
literatur
search
growth
virus
mdck
cell
publish
previous
studi
standard
amount
infecti
unit
per
ml
cultur
inocul
mdck
cell
cell
grown
least
day
day
slowgrow
virus
cdm
growth
medium
high
dilut
passag
avoid
sampl
suspend
cell
medium
taken
regular
interv
test
viru
adequ
amount
fresh
medium
ad
sampl
maintain
cell
growth
none
nt
coronaviru
none
coronaviru
borderlin
none
resp
syncyti
viru
none
rsv
question
none
adenoviru
none
nt
human
metapneumoviru
none
nt
parainfluenza
viru
none
nt
bocaviru
none
nt
three
doubl
infect
count
individu
maximum
dilut
origin
specimen
passag
passag
done
passag
supernat
nt
test
tabl
hmpv
growth
mycoplasma
hyorhini
chlamydia
trachomati
assess
studi
high
viru
growth
observ
parainfluenzaviru
herp
simplex
viru
slow
growth
seen
mammalian
reoviru
question
result
low
growth
note
two
avian
reoviru
growth
observ
virus
agent
test
infecti
titer
declin
case
longer
detect
day
cultiv
stabl
virus
viru
titer
persit
longer
base
upon
studi
support
result
systemat
literatur
search
applic
standard
adher
grow
mdck
cell
mdck
suspens
cell
support
growth
limit
rang
virus
context
relev
virus
influenza
viru
parainfluenza
viru
reoviru
herp
simplex
viru
permiss
spectrum
similar
seen
embryon
egg
therefor
like
embryon
egg
use
current
influenza
vaccin
manufactur
mdck
cell
act
effect
barrier
wide
rang
adventiti
agent
moreov
mdck
cell
support
replic
mani
avian
virus
particular
relev
avian
viru
contamin
introduc
process
prior
passag
vaccin
viru
strain
embryon
egg
clinic
specimen
use
studi
collect
peak
influenza
season
februari
march
order
gain
inform
isol
rate
mdck
cell
suspens
cultur
result
studi
publish
elsewher
consid
select
specimen
high
percentag
influenzaposit
result
surpris
signific
number
sampl
also
test
posit
virus
adenoviru
bocaviru
coronaviru
enteroviru
metapneumoviru
hmpv
parainfluenza
viru
piv
rhinoviru
respiratori
syncyti
viru
rsv
except
rsv
piv
virus
also
detect
coinfect
togeth
influenza
viru
coinfect
togeth
influenza
virus
also
publish
previous
rsv
piv
hmpv
adenoviru
bocaviru
although
overal
frequenc
compar
low
previou
report
base
pcr
detect
method
appli
restrict
viru
spectrum
resplex
ii
method
unabl
find
report
coinfect
influenza
viru
virus
identifi
via
cell
cultur
isol
method
although
doubleinfect
studi
materi
certainli
use
high
number
indic
cell
cultur
select
support
replic
specif
virus
addit
viru
identif
method
use
less
specif
less
sensit
pcrbase
method
purpos
studi
resplex
ii
multiplex
pcr
method
chosen
combin
detect
wide
rang
relev
respiratori
virus
simpl
applic
onetub
assay
rapid
result
one
test
run
particularli
could
appli
avail
small
volum
current
limit
inform
avail
sensit
specif
resplex
ii
v
test
kit
compar
novel
resplex
iii
assay
exist
techniqu
detect
subtyp
influenza
viru
influenza
season
methodolog
must
necessarili
make
compromis
exampl
regard
amplif
condit
first
cycl
specif
primer
thu
expect
sensit
monoplex
pcr
compar
inhous
quantit
realtim
pcr
influenza
viru
detect
limit
tcid
ml
fresh
influenza
viru
harvest
resplexii
test
appear
log
step
less
sensit
major
posit
result
obtain
resplexii
test
could
confirm
independ
convent
publish
inhous
qrtpcr
commerci
avail
pcr
method
use
target
region
viral
genom
appli
influenza
posit
sampl
rsv
b
posit
sampl
test
adenoviru
posit
sampl
bocaviru
posit
sampl
includ
one
question
resplex
result
posit
coronaviru
sampl
includ
question
resplex
result
differ
found
parainfluenza
viru
sampl
resplex
result
could
confirm
likewis
rhinoviru
sampl
enteroviru
sampl
test
neg
independ
pcr
posit
resplex
method
remain
determin
whether
observ
discrep
weak
resplex
system
independ
pcr
howev
manufactur
resplex
method
confirm
certain
crossreact
enterovirus
rhinovirus
conserv
utr
region
use
target
pcr
primer
sinc
known
reoviru
may
grow
mdck
cell
also
screen
mani
sampl
inhous
reoviru
qrtpcr
specif
mammalian
orthoreoviru
conserv
region
inner
capsid
gene
sampl
viru
detect
resplex
method
prefer
use
reoviru
pcr
reoviru
found
specimen
suffici
materi
still
avail
wherea
specif
viru
growth
studi
summar
discuss
appli
cellcultur
adapt
viru
strain
studi
report
use
unadapt
field
viru
strain
technic
condit
appli
influenza
viru
isol
passag
studi
confirm
isol
influenza
virus
mdck
cell
effect
reduc
coinfect
virus
two
passag
total
dilut
origin
specimen
adeno
boca
corona
entero
rhinovirus
longer
detect
influenza
virus
recov
remain
detect
viru
upon
passag
high
dilut
inocula
short
incub
period
day
harvest
next
passag
condit
normal
appli
effect
grow
influenza
virus
condit
certainli
contribut
rapid
loss
contamin
virus
virus
present
high
titer
grow
rapidli
without
adapt
would
abl
surviv
passag
second
seri
passag
also
monitor
specimen
contain
influenza
viru
posit
respiratori
virus
specimen
interfer
compet
influenza
viru
growth
exclud
cultur
condit
differ
lower
inoculum
dilut
use
sampleharvest
dilut
cultur
lowest
standard
dilut
appli
recov
lowtitr
influenza
viru
also
condit
posit
result
differ
virus
becam
neg
passag
total
dilut
origin
specimen
factor
similar
passag
conduct
adher
vero
cell
vero
seed
sever
posit
sampl
adenoviru
rhinoviru
enteroviru
metapneumoviru
bocaviru
remain
posit
passag
howev
except
adenoviru
count
increas
drop
data
shown
result
demonstr
practic
condit
appli
grow
influenza
virus
contamin
virus
effect
remov
passag
mdck
cell
combin
superior
isol
effici
mdck
cell
appear
highli
suitabl
use
altern
embryon
egg
isol
propag
candid
vaccin
virus
